In vivo最新文献

{"title":"Activation of Invariant Natural Killer T Cells Enhances Ischemia-Reperfusion Injury in Steatotic Mouse Livers.","authors":"Y U Kuroda, Yoshiya Ito, Nobuyuki Nishizawa, Mina Tanabe, Takuya Goto, Atsushi Yamashita, Kanako Hosono, Masashi Satoh, Yusuke Kumamoto, Naoki Hiki, Hideki Amano","doi":"10.21873/invivo.13939","DOIUrl":"https://doi.org/10.21873/invivo.13939","url":null,"abstract":"<p><strong>Background/aim: </strong>Hepatic steatosis is a significant independent risk factor for liver surgery because of its vulnerability to ischemia-reperfusion (IR) injury. Invariant natural killer T (iNKT) cells contribute to IR injury in healthy liver. We previously reported that activated iNKT cells mitigate liver IR injury and facilitate liver repair by interacting with macrophages. This study aimed to assess the role of activated iNKT cells in IR injury in steatotic livers.</p><p><strong>Materials and methods: </strong>Male C57/BL6 mice were fed a normal diet (ND) or high-fat diet (HFD) for 12 weeks before liver IR. iNKT cells were activated by intraperitoneal injection of α-galactosylceramide (α-GC) into HFD-fed mice. This study assessed liver injury, cytokine levels, and immune cell accumulation.</p><p><strong>Results: </strong>HFD-fed mice exhibited increased levels of liver injury, pro-inflammatory mediators, and macrophages compared to those of ND-fed mice. Administration of α-GC to HFD-fed mice enhanced liver IR injury that was associated with increased numbers of iNKT cells and pro-inflammatory macrophages compared with those in the vehicle-treated group. Additionally, liver repair was delayed in α-GC-treated HFD-fed mice, as demonstrated by the increased necrotic area and decreased proliferating cell nuclear antigen expression. This was accompanied by reduced levels of anti-inflammatory mediators and reparative macrophages. Pro-inflammatory cytokine levels were increased in activated hepatic iNKT cells co-cultured with macrophages isolated from HFD-fed mice.</p><p><strong>Conclusion: </strong>The activation of hepatic iNKT cells aggravates steatotic liver IR injury by upregulating pro-inflammatory mediators and macrophages, while suppressing anti-inflammatory mediators and reparative macrophages.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1355-1369"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Hydrogen Capsule Therapy for Primary Biliary Cholangitis With Elevated IgG4: A Case Report on Immune Marker Normalization.","authors":"Yun-Ting Lin, Jeng-Wei Lu, Jung-Chun Lin, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Hsiao-Chen Liu, Kuang-Yih Wang, Feng-Cheng Liu","doi":"10.21873/invivo.13968","DOIUrl":"https://doi.org/10.21873/invivo.13968","url":null,"abstract":"<p><strong>Background/aim: </strong>Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by bile duct destruction, cholestasis, and inflammation, often leading to fibrosis and cirrhosis. While ursodeoxycholic acid (UDCA) is the standard treatment, some patients exhibit suboptimal responses, necessitating adjunctive therapies. Molecular hydrogen (H₂), known for its antioxidant and anti-inflammatory properties, has shown potential in mitigating oxidative stress and immune dysregulation in autoimmune liver diseases. This case report evaluates the therapeutic efficacy of H₂ capsules in managing PBC with elevated liver enzymes and immune dysregulation.</p><p><strong>Case report: </strong>A 44-year-old male with PBC, splenomegaly, and elevated IgG4 levels presented with acute cholestatic hepatitis. Laboratory tests revealed significantly elevated aspartate transaminase (AST) (279 U/l) and alanine aminotransferase (ALT) (183 U/l). Despite UDCA therapy, liver enzymes remained persistently high. On August 30, 2024, molecular hydrogen capsule therapy was introduced as adjunctive treatment. Over four months, AST and ALT levels declined to 95 U/l and 70 U/l, respectively, without adverse effects. Immune markers (KLRG-1, PD-1, and Tim3), previously reduced during PBC flares, normalized post-treatment. Imaging confirmed stable fibrosis, and IgG4 levels decreased, suggesting reduced autoimmune activity. The patient also reported improvements in fatigue and pruritus, enhancing overall quality of life.</p><p><strong>Conclusion: </strong>Molecular hydrogen capsules therapy may serve as a safe and effective adjunctive treatment for PBC, contributing to improved liver enzyme levels, immune regulation, and patient well-being. Further studies are warranted to validate these findings and establish standardized treatment protocols in autoimmune liver diseases.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1669-1675"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colposcopic Alterations Are More Frequent in Smokers and Appear at a Younger Age.","authors":"Diego Erasun Mora, Ana Vázquez Del Campo, Alazne DE Castro Momioto, Alberto Muñoz Solano, Jose Schneider","doi":"10.21873/invivo.13946","DOIUrl":"https://doi.org/10.21873/invivo.13946","url":null,"abstract":"<p><strong>Background/aim: </strong>Tobacco use is a recognized cofactor risk for cervical cancer induced by high-risk Human Papilloma Virus (HR-HPV). This study aimed to evaluate the specific influence of tobacco use on colposcopic examination results in women infected by HR-HPV.</p><p><strong>Patients and methods: </strong>HR-HPV-positive women undergoing a loop electrosurgical excision procedure (LLETZ) after colposcopic examination were considered for this study. A total of 819 patients from a regional screening program were included, of whom 320 were smokers and 499 non-smokers.</p><p><strong>Results: </strong>Smokers were significantly younger (41.1 <i>vs.</i> 43.8, <i>p</i><0.01), more frequently exhibited grade II colposcopic changes (63.9% <i>vs.</i> 53.3%, <i>p</i><0.05), had worse histopathological outcomes (CIN2+: 75.7% <i>vs.</i> 67.9%, <i>p</i><0.05; CIN3+: 51.4% <i>vs.</i> 44.0%, <i>p</i><0.05), and higher rates of affected surgical margins, with borderline significance (22.6% <i>vs.</i> 17.8%, <i>p</i>=0.055). While no significant differences in viral clearance were observed at six months, smokers showed a trend toward worse outcomes at two years (<i>p</i>=0.07).</p><p><strong>Conclusion: </strong>Smoking in any amount is associated with worse colposcopic and histopathological findings, and this occurs at younger ages.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1453-1457"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Diagnostic Yield of Whole-body Computed Tomography in Dogs and Cats in the Oncology Setting.","authors":"Maria DE Almeida, Hugo Gregório, André Pereira, Felisbina L Queiroga","doi":"10.21873/invivo.13933","DOIUrl":"https://doi.org/10.21873/invivo.13933","url":null,"abstract":"<p><strong>Background/aim: </strong>Clinical staging has become essential in veterinary oncology. It is crucial for creating effective treatment plans and predicting outcomes. Whole-body computed tomography (WBCT) can serve as a comprehensive staging examination, offering a detailed view of a patient's internal anatomy. This retrospective study aimed to assess the diagnostic yield of WBCT in diagnosing cancer in dogs and cats.</p><p><strong>Patients and methods: </strong>We reviewed medical records of cats and dogs that underwent a WBCT scan between January 2016 and May 2023. Only cases with a confirmed cytological or histological diagnosis of the primary tumor and complete medical records were considered. We collected data on histological diagnoses and diagnostic methods used.</p><p><strong>Results: </strong>Our study included 57 animals that underwent WBCT for cancer-related reasons. Metastases were detected in 14 dogs, with four showing metastases in multiple locations, five in the lungs, three in the lymph nodes, one in the skeleton, and one in the liver, yielding a diagnostic rate of 31.8%. In cats, metastases were detected in six cases (five in the lungs and one in the lymph nodes), with a diagnostic yield of 46.2%. WBCT identified metastasis in over 35% of cases, including those outside the thoracic and abdominal cavities, indicating potentially greater accuracy than radiography and ultrasound.</p><p><strong>Conclusion: </strong>WBCT is an effective and safe method for tumor staging and oncological diagnosis in dogs and cats.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1293-1302"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Anemia Is an Independent Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment.","authors":"Kiyoko Shimada, Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Ryuki Esashi, Momoko Fukuda, Mihwa Ju, Sosuke Yamamoto, Keisuke Kazama, Natsumi Kamiya, Naoko Okuda, Ayako Tamagawa, Koji Numata, Mamoru Uchiyama, Aya Saito, Norio Yukawa","doi":"10.21873/invivo.13969","DOIUrl":"https://doi.org/10.21873/invivo.13969","url":null,"abstract":"<p><strong>Background/aim: </strong>We retrospectively evaluated the clinical impact of anemia during the perioperative period on both short- and long-term oncological outcomes in patients with resectable esophageal cancer who received curative treatment.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed the medical records and collected data from consecutive patients with esophageal cancer who underwent curative resection at Yokohama City University from 2005 to 2022.</p><p><strong>Results: </strong>A total of 198 patients were included in this study. According to previous studies and the 3- and 5- year overall survival rates, a hemoglobin level of 11 g/dl was selected as the optimal cutoff value in the present study; preoperative hemoglobin of <11 g/dl and >11 g/dl were observed in 34 patients (Hb-low group) and 164 patients (Hb-high group), respectively. The 3- and 5-year OS rates were 39.1% and 34.8%, respectively, in the Hb-low group and 70.3% and 62.1% in the Hb-high group. There were significant differences between the two groups (<i>p</i>=0.003). Univariate and multivariate analyses demonstrated that the preoperative Hb level was as an independent prognostic factor for OS [hazard ratio (HR)=1.809; 95% confidence interval (CI)=1.073-3.050, <i>p</i>=0.026]. Moreover, the 3- and 5-year recurrence-free survival (RFS) rates were 16.6% and 16.6%, respectively, in the Hb-low group and 51.8% and 45.1% in the Hb-high group (<i>p</i><0.001). In the multivariate analysis, the preoperative Hb status was also selected as an independent prognostic factor for RFS (HR=1.977; 95%CI=1.240-3.151 <i>p</i>=0.004).</p><p><strong>Conclusion: </strong>Preoperative anemia is an independent prognostic factor in patients with esophageal cancer. Our results suggest its potential significance in the treatment and management of these patients.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1676-1684"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenic Variants and Allele Loss of the NF2 and LZTR1 Gene in Sporadic Vestibular Schwannoma.","authors":"Maria Breun, Tim Schulz, Camelia M Monoranu, Ralf-Ingo Ernestus, Cordula Matthies, Mario Löhr, Lan Kluwe","doi":"10.21873/invivo.13929","DOIUrl":"https://doi.org/10.21873/invivo.13929","url":null,"abstract":"<p><strong>Background/aim: </strong>Pathogenic variants and allele-loss of the <i>NF2</i> gene with Merlin loss as consequence is the driving genetic event for vestibular schwannoma development. Our knowledge about the pathogenic <i>NF2</i> variants in sporadic vestibular schwannoma is insufficient. Therefore, we analyzed a cohort of sporadic vestibular schwannomas by panel-sequencing.</p><p><strong>Patients and methods: </strong>Forty-one sporadic vestibular schwannomas from 26 male and 15 female patients were included. DNA from tumor tissues was sequenced with a custom panel for the <i>NF2</i> and <i>LZTR1</i> genes. Allele-loss of the <i>NF2</i> locus was also examined using multiplex-ligation-dependent probe-amplification. These genetic data were correlated with clinical parameters including hearing, tumor extension and growth.</p><p><strong>Results: </strong>Among the 41 tumor samples, 34 had one pathogenic variant or an allele-loss of <i>NF2</i> gene and one tumor showed a pathogenic variant in the <i>LZTR1</i> gene. Allele frequencies of the total of 46 pathogenic variants varied from 0.05 to 0.82, and none of these variants was found in blood. For 6 tumors, no pathogenic variants were found while 4 of them had allele-loss of the <i>NF2</i> gene. When the tumors were divided into 3 groups according to the counts of inactivating events (pathogenic variants and allele loss), the clinical parameters including hearing, tumor structure in MRI, tumor growth, tumor size and postoperative facial function did not differ significantly.</p><p><strong>Conclusion: </strong>There was no correlation between phenotype and genetic alterations of the <i>NF2 or LZTR1</i> gene in sporadic schwannomas. Genetic inactivating events are the precondition for the development of vestibular schwannomas but do not influence their growth and other features.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1251-1261"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gefitinib Facilitates Bone Fracture Healing <i>via</i> Inhibition of the EGFR Pathway and Counteracting SOX9-driven Bone Metabolic Reprogramming.","authors":"Ning Xu, Gongwu Yuan, Wenbo Zeng, Ximing Liu, M A Wan, Suyang Xu, Yikang Bi, Hai Hu, Yafeng Xu, Shenghui Lan","doi":"10.21873/invivo.13942","DOIUrl":"https://doi.org/10.21873/invivo.13942","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the role of epidermal growth factor receptor (EGFR) inhibition in enhancing bone fracture healing by modulating box transcription factor 9 (SOX9) and bone metabolism.</p><p><strong>Materials and methods: </strong>A rat femoral fracture model was used. Techniques included histological analysis, X-ray scoring, micro-computed tomography, immunohistochemistry, and biomechanical testing. Serum markers were analyzed with enzyme-linked immunosorbent assay, while quantitative real-time polymerase chain reaction and western blotting assessed molecular pathways. Metabolic changes were measured using a Seahorse analyzer. An EGFR inhibitor, gefitinib, was used to examine its impact on periosteal stem cell differentiation and metabolism.</p><p><strong>Results: </strong>EGFR inhibition improved bone callus formation and quality, increased cartilage callus, and upregulated bone formation markers. Gefitinib enhanced oxidative phosphorylation and fatty acid oxidation, counteracting negative effects from lipid-reduced serum on osteoblastic differentiation of periosteal stem cell. SOX9 overexpression reduced the benefits of EGFR inhibition.</p><p><strong>Conclusion: </strong>Gefitinib enhances bone fracture healing by modulating lipid metabolism through SOX9, suggesting its potential as a therapeutic agent for improving fracture outcomes.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1394-1413"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Genetic Mutations in Hyperhomocysteinemia and Metabolic Syndrome on Physiological Parameters and Quality of Life in Healthy Individuals.","authors":"Bogdan Mihai Tarcau, Andra Negru, Alexandra Manuela Buzle, Timea Claudia Ghitea, Eleonora Marian","doi":"10.21873/invivo.13972","DOIUrl":"https://doi.org/10.21873/invivo.13972","url":null,"abstract":"<p><strong>Background/aim: </strong>Hyperhomocysteinemia (HH) is a metabolic condition linked to cardiovascular and cognitive health risks. This study investigated the prevalence of HH and cardiovascular metabolic syndrome (MS) among patients with symptoms such as fatigue, joint pain, muscle weakness, vertigo, paresthesia, and aphthous stomatitis. The objective was to explore the associations between HH, MS, and quality of life, emphasizing the role of personalized dietary interventions.</p><p><strong>Patients and methods: </strong>A prospective study was conducted between 2019 and 2023, including 86 patients aged 18 years or older who underwent nutrigenetic testing and provided anthropometric data. Participants were divided into three groups: those with HH (45.3%), those without HH or MS (31.4%), and those with MS but without HH (23.3%). Nutrigenetic analyses assessed genetic predispositions related to nutrient metabolism.</p><p><strong>Results: </strong>Patients with HH exhibited reduced quality of life, with lower Short Form-12 Health Survey (SF-12) scores compared to other groups. Sex-specific nutrient needs and age-related changes in dietary requirements were identified. Metabolic conditions, including obesity, hypertension, and hypercholesterolemia, inversely impacted nutrient utilization. Physical activity positively correlated with higher demands for folic acid, vitamin B12, zinc, and magnesium.</p><p><strong>Conclusion: </strong>Nutritional interventions targeting these needs effectively improved metabolic health and alleviated symptoms. HH significantly impacts quality of life and metabolic health. Personalized dietary and lifestyle modifications tailored to genetic predispositions, sex, and age are critical for mitigating cardiometabolic risks. These findings lay the groundwork for targeted interventions aimed at improving health outcomes in individuals with HH and MS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1703-1718"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Serum Levels of Irisin, Visfatin and Adiponectin as Potential Independent Risk Factors for Diabetic Nephropathy Progression in Patients With Type 2 Diabetes Mellitus.","authors":"Basem H Elesawy, Ahmad El Askary, Osama M Mehanna, Elsayed A Elmorsy, Mohamed M Khalifa, Sanaa E Ali, Amal Abd El Hafez","doi":"10.21873/invivo.13962","DOIUrl":"https://doi.org/10.21873/invivo.13962","url":null,"abstract":"<p><strong>Background/aim: </strong>Diabetic nephropathy (DN) is a common devastating complication in type 2 diabetes mellitus (T2DM). In order to investigate novel DN biomarkers, we evaluated serum levels of irisin, adiponectin, visfatin and interleukin 4 (IL-4) in patients with T2DM with normo-, micro- and macro-albuminuria and compared their means with non-diabetic controls.</p><p><strong>Patients and methods: </strong>Clinical data and routine laboratory parameters of metabolic and renal function status were determined in blood and urine samples obtained from 169 participants, divided into four groups according to the presence of diabetes and albuminuria using appropriate biochemical assays/calculations. Serum levels of irisin, adiponectin, visfatin and interleukin 4 (IL4) were assessed using enzyme-linked immunosorbent assay. Means of all tested parameters and biomarkers were compared using appropriate statistical methods. Logistic regression was used to determine albuminuria risk factors in T2DM as an indicator for DN.</p><p><strong>Results: </strong>All tested parameters differed significantly among T2DM groups and controls (<i>p</i><0.001). Irisin, adiponectin, visfatin and IL4 significantly increased in T2DM patients with significant increasing albuminuria. Along with hemoglobin A1C, irisin was the most highly significant risk factor for development and progression of albuminuria (p<0.001). Adiponectin was also a significant independent risk factor (<i>p</i>=0.009), whilst visfatin and IL4 conferred no significant risk.</p><p><strong>Conclusion: </strong>High irisin levels in normo-albuminuric patients indicates their potential to develop DN even prior to detectable albuminuria. Both irisin and adiponectin may be considered as potential biomarkers indicating risk for DN progression in T2DM that might be therapeutically targeted.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1615-1624"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Common miRNAs Differentially Expressed in Periodontitis and Pancreatic Cancer.","authors":"Deniz Sunnetci-Akkoyunlu, Cansu Ugurtas, Nurhan Kulcu-Sarikaya, Tolgahan Ozer, Naci Cine, Seda Eren-Keskin, Aylin Kanli, Hakan Savli","doi":"10.21873/invivo.13944","DOIUrl":"https://doi.org/10.21873/invivo.13944","url":null,"abstract":"<p><strong>Background/aim: </strong>Periodontitis is a prevalent multifactorial, oral infectious disease and is considered a high-risk factor for pancreatic cancer. Nevertheless, there is limited understanding of the underlying epigenetic mechanisms governing this relationship. The aim of this study was to identify dysregulated miRNAs associated with periodontitis and pancreatic cancer, along with their related genes, signaling pathways, and compounds.</p><p><strong>Materials and methods: </strong>miRNA expression datasets for tissues affected by periodontitis and pancreatic cancer were obtained from the Gene Expression Omnibus database. miRNAs differentially expressed relative to normal tissues were detected, and those common to both datasets were determined. Further bioinformatics approaches were used to explore the association of common differentially expressed miRNAs with periodontitis and pancreatic cancer.</p><p><strong>Results: </strong>Twenty shared, differentially expressed miRNAs were identified; 14 exhibited similar expression patterns in both diseases. Among these common differentially expressed miRNAs, 10 were found to be overexpressed. hsa-miR-155, hsa-miR-186, hsa-miR-765, hsa-miR-211 and hsa-miR-375 were the top miRNA nodes in the gene network, with hsa-mir-155 being the sole miRNA node in the transcription factor network. Top candidate miRNA-dysregulated genes included superoxide dismutase 2 (SOD2), nuclear FMR1 interacting protein 2 (NUFIP2), SFT2 domain-containing 2 (SFT2D2), thioredoxin-interacting protein (TXNIP), and cyclin D1 (CCND1), while top dysregulated transcription factors were Argonaute RISC catalytic component 2 (AGO2), AKT serine/threonine kinase 1 (AKT1), BCL6 transcription repressor (BCL6), breakpoint cluster region (BCR), and BRCA1 DNA repair associated (BRCA1). Relevant compounds for targeting these emerged, including 5-fluorouracil, gemcitabine, doxorubicin, ascorbate, diethylstilbestrol, and temozolomide.</p><p><strong>Conclusion: </strong>Our study suggests candidate molecular mechanisms linking periodontitis to pancreatic cancer, highlighting potential compounds that may target both diseases. These findings provide a foundation for guiding future fundamental and clinical research.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1422-1439"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}